Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Change in Receivables (2024 - 2025)

Gossamer Bio (GOSS) has 2 years of Change in Receivables data on record, last reported at $1.7 million in Q3 2025.

  • For Q3 2025, Change in Receivables fell 43.76% year-over-year to $1.7 million; the TTM value through Sep 2025 reached $2.7 million, down 59.7%, while the annual FY2024 figure was $5.3 million, N/A changed from the prior year.
  • Change in Receivables reached $1.7 million in Q3 2025 per GOSS's latest filing, up from $996000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $3.6 million in Q2 2024 and bottomed at -$1.2 million in Q4 2024.